Therapeutic potential of monteplase in acute myocardial infarction.
Thrombolysis with conventional thrombolytic agents prior to percutaneous coronary intervention (PCI) has had no impact on the treatment of acute myocardial infarction (AMI). However, the development of mutant tissue type plasminogen activators (mt-PA) has prompted us to reassess the combination of thrombolysis and PCI. Monteplase is a newly developed mt-PA that can be administered as a single intravenous bolus injection. The results of the COMA (COmbining Monteplase with Angioplasty) trial, suggest that monteplase administration prior to emergent PCI in AMI improves 6-month outcomes and possibly the long-term prognosis of myocardial infarction. Combining monteplase administration on presentation at a community hospital with prompt transfer to a tertiary center for PCI would be an ideal strategy for the treatment of AMI.
Department of Cardiovascular and Renal Medicine, Saga University Faculty of Medicine, Saga, Japan. inouete@med.saga-u.ac.jp
Teruo
T
Inoue
Ryoichi
R
Nishiki
Manabu
M
Kageyama
Koichi
K
Node
D000208:Acute Disease; D000595:Amino Acid Sequence; D000800:Angioplasty, Balloon; D002986:Clinical Trials as Topic; D005343:Fibrinolytic Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology; D017395:Plasminogen Activator Inhibitor 1 / Q000502:physiology; D010960:Plasminogen Activators / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D011487:Protein Conformation
D005343:Fibrinolytic Agents; D017395:Plasminogen Activator Inhibitor 1; C468277:monteplase; D010960:Plasminogen Activators